SOUTH PLAINFIELD, N.J., June 11, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Ronald C. Renaud, Jr. to the company's Board of Directors. Mr. Renaud has served as the President and Chief Executive Officer of Idenix Pharmaceuticals, Inc., a public biopharmaceutical company, since October 2010.
"We are delighted to welcome Ron to PTC's Board of Directors. Ron brings tremendous skills and experience to PTC that will be invaluable to our future growth and success. His demonstrated leadership experience in building successful biotechnology companies, his former background as an equity research analyst and his deep knowledge of the life sciences industry will provide valuable contributions to our company," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc.
Mr. Renaud previously served as the Chief Financial Officer of Idenix from the time he joined Idenix in June 2007 and was additionally appointed chief business officer in June 2010. Prior to joining Idenix, Mr. Renaud served as senior vice president and chief financial officer of Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, from February 2006 to May 2007. He was a senior research analyst and global sector coordinator for JP Morgan Securities from May 2004 until February 2006, where he was responsible for the biotechnology equity research effort, covering all ranges of capitalized biotechnology companies. He also spent more than five years at Amgen, where he held positions in clinical research, investor relations and finance. Mr. Renaud holds a B.A. from St. Anselm College and an M.B.A. from the Marshall School of Business at the University of Southern California.
"I am thrilled to join PTC during this exciting time in the company's history," said Mr. Renaud. "I look forward to supporting the commercialization of Translarna™ in the EU, the advancement of Translarna™ in the US, as well as the continued growth and development of PTC's broad pipeline."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts